

해외 바이오의약품 임상 현황 (2020.08.24~2020.08.31)

한국바이오의약품협회, 2020.9.1.
출처: ClinicalTrials.gov

○ 미국 23건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04524273	Myasthenia Gravis Inebilizumab Trial	Myasthenia Gravis	Drug: inebilizumab Drug: IV Placebo	Viela Bio	Phase 3
NCT04498377	Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19	Covid19	Biological: F-652 Biological: Placebo	Generon (Shanghai) Corporation Ltd.	Phase 2
NCT04498117	Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery	Carcinoma, Ovarian Epithelial Ovarian Neoplasms Ovarian Cancer Ovarian Serous Adenocarcinoma Fallopian Tube Neoplasms Fallopian Tube Adenocarcinoma Fallopian Tube Serous Adenocarcinoma Peritoneal Cancer Peritoneal Carcinoma Peritoneal Neoplasms	Biological: Oregovomab Drug: Paclitaxel Drug: Carboplatin Biological: Placebo	OncoQuest Pharmaceuticals Inc. Gynecologic Oncology Group Iqvia Pty Ltd	Phase 3
NCT04462406	Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial	Advanced Melanoma Clinical Stage III Cutaneous Melanoma AJCC v8 Clinical Stage IV Cutaneous Melanoma AJCC v8 Melanoma of Unknown Primary Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 Pathologic Stage IIID Cutaneous Melanoma AJCC v8 Pathologic Stage IV Cutaneous Melanoma AJCC v8 Unresectable Acral Lentiginous Melanoma Unresectable Melanoma Unresectable Mucosal Melanoma	Biological: Ipilimumab Biological: Nivolumab Other: Patient Observation Biological: Pembrolizumab	ECOG-ACRIN Cancer Research Group National Cancer Institute (NCI) Eastern Cooperative Oncology Group	Phase 2
NCT04414540	Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients	Head and Neck Squamous Cell Carcinoma	Drug: Metformin Extended Release Oral Tablet Drug: Pembrolizumab	Trisha Wise-Draper American Cancer Society, Inc. University of Cincinnati	Phase 2
NCT04242264	Phase 2 Shigella Vaccine and Challenge	Immunisation Shigella Infection	Other: Placebo Biological: Shigella sonnei strain 53G Biological: WRSs2	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2
NCT04239157	Canakinumab and Anacitidine for the Treatment of Low or Intermediate Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia	Chronic Myelomonocytic Leukemia Myelodysplastic Syndrome Recurrent Chronic Myelomonocytic Leukemia Recurrent Myelodysplastic Syndrome Refractory Chronic Myelomonocytic Leukemia Refractory Myelodysplastic Syndrome	Biological: Canakinumab	M.D. Anderson Cancer Center National Cancer Institute (NCI) Novartis	Phase 2
NCT04230031	Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma	Multiple Myeloma	Drug: Daratumumab	Saad Z. Usmani, MD Janssen Research & Development, LLC Atrium Health	Phase 2
NCT04174560	Phase I Norovirus Challenge Model	Gastroenteritis Norovirus	Biological: Norovirus GII.4 Challenge Pool	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1
NCT04515576	A Study of LY3493269 in Participants With Type 2 Diabetes	Diabetes Mellitus, Type 2	Drug: LY3493269 Drug: Dulaglutide Drug: Placebo	Eli Lilly and Company	Phase 1
NCT04511975	A Study Evaluating the Safety and Efficacy of IBI188 in Combination With AZA in Subjects With Newly Diagnosed MDS	MDS	Drug: IBI188 Drug: Azacitidine	Innovent Biologics (Suzhou) Co. Ltd.	Phase 1
NCT04524455	A Study of Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Acute Lymphoblastic Leukemia (ALL)	Acute Lymphoblastic Leukemia	Drug: Blinatumomab Drug: AMG 404 Drug: Dexamethasone Premedication	Amgen	Phase 1
NCT04482309	A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors	Bladder Cancer, Biliary Tract Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Pancreatic Cancer, Rare Tumors	Drug: Trastuzumab deruxtecan	AstraZeneca Daiichi Sankyo Co., Ltd.	Phase 2
NCT04468971	Regulatory T Cell infusion for Lung Injury Due to COVID-19 Pneumonia	COVID19 ARDS	Biological: CK0802 Drug: Placebo	Cellenkos, Inc.	Phase 1
NCT04530110	A Study to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents	Migraine	Drug: Fremanezumab	Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries	Phase 3
NCT04529096	Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Chronic Low Back Pain	Chronic Low-back Pain	Drug: LY3016859 Drug: Placebo	Eli Lilly and Company	Phase 2
NCT04513925	A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)	Non-small Cell Lung Cancer (NSCLC)	Drug: Atezolizumab Drug: Tiragolumab Drug: Durvalumab	Hoffmann-La Roche	Phase 3
NCT04493502	A Study of LY3041658 in Adults With Hidradenitis Suppurativa	Hidradenitis Suppurativa	Drug: Placebo Drug: LY3041658	Eli Lilly and Company	Phase 2
NCT04471428	Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy	Carcinoma, Non-Small-Cell Lung	Drug: Cabozantinib Drug: Atezolizumab Drug: Docetaxel	Hoffmann-La Roche Exelixis	Phase 3
NCT04376827	A Study of Guselkumab in Participants With Active Lupus Nephritis	Lupus Nephritis	Drug: Guselkumab Dose 1 Drug: Placebo Drug: Guselkumab Dose 2 Drug: Standard-of-care treatment	Janssen Research & Development, LLC	Phase 2
NCT04264806	A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)	Myelodysplastic Syndromes Leukemia, Myelomonocytic, Chronic	Drug: Azacitidine Drug: Cusatuzumab	Janssen Research & Development, LLC argenx BVBA	Phase 2
NCT04497961	A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide	Multiple Myeloma	Drug: Lenalidomide Drug: Daratumumab Behavioral: Questionnaires	Memorial Sloan Kettering Cancer Center Janssen Scientific Affairs, LLC	Phase 2
NCT04432207	A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer	Non Small Cell Lung Cancer Non Small Cell Lung Cancer Stage IIIB Non-small Cell Lung Cancer Stage IV Squamous Non-small-cell Lung Cancer Large Cell Carcinoma Lung Adenocarcinoma Lung	Drug: IMU-201 (administered as PD1-Vaxx) Drug: Standard of care treatment for NSCLC	Imugene Limited	Phase 1

해외 바이오의약품 임상 현황 (2020.08.24~2020.08.31)

한국바이오의약품협회, 2020.9.1.
출처: ClinicalTrials.gov

○ 영국 4건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04513704	A Clinical Trial Comparing Semaglutide in Healthy People Who Eat and Take the Medicine at Different Times	Healthy Volunteers Type 2 Diabetes	Drug: Oral Semaglutide	Novo Nordisk A/S	Phase 1
NCT04471428	Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy	Carcinoma, Non-Small-Cell Lung	Drug: Cabozantinib Drug: Atezolizumab Drug: Docetaxel	Hoffmann-La Roche Exelixis	Phase 3
NCT04513925	A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)	Non-small Cell Lung Cancer (NSCLC)	Drug: Atezolizumab Drug: Tiragolumab Drug: Durvalumab	Hoffmann-La Roche	Phase 3
NCT04264806	A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)	Myelodysplastic Syndromes Leukemia, Myelomonocytic, Chronic	Drug: Azacitidine Drug: Cusatuzumab	Janssen Research & Development, LLC argenx BVBA	Phase 2

○ 프랑스 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04471428	Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy	Carcinoma, Non-Small-Cell Lung	Drug: Cabozantinib Drug: Atezolizumab Drug: Docetaxel	Hoffmann-La Roche Exelixis	Phase 3
NCT04513925	A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)	Non-small Cell Lung Cancer (NSCLC)	Drug: Atezolizumab Drug: Tiragolumab Drug: Durvalumab	Hoffmann-La Roche	Phase 3
NCT04264806	A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)	Myelodysplastic Syndromes Leukemia, Myelomonocytic, Chronic	Drug: Azacitidine Drug: Cusatuzumab	Janssen Research & Development, LLC argenx BVBA	Phase 2

○ 독일 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04471428	Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy	Carcinoma, Non-Small-Cell Lung	Drug: Cabozantinib Drug: Atezolizumab Drug: Docetaxel	Hoffmann-La Roche Exelixis	Phase 3
NCT04513925	A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)	Non-small Cell Lung Cancer (NSCLC)	Drug: Atezolizumab Drug: Tiragolumab Drug: Durvalumab	Hoffmann-La Roche	Phase 3
NCT04264806	A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)	Myelodysplastic Syndromes Leukemia, Myelomonocytic, Chronic	Drug: Azacitidine Drug: Cusatuzumab	Janssen Research & Development, LLC argenx BVBA	Phase 2
NCT04268823	Clinical Study to Assess the Mode of Action of QBW251 in Patients With Chronic Obstructive Pulmonary Disease (COPD)	Chronic Obstructive Pulmonary Disease	Drug: QBW251 Drug: Placebo	Novartis Pharmaceuticals Novartis	Phase 2

○ 중국 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04530656	Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)	COVID-19	Biological: Two doses of middle-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28 Biological: Two doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28 Biological: Three doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 14, 28 Biological: Two doses of placebo at the schedule of day 0, 28 Biological: Three doses of placebo at the schedule of day 0, 14, 28	Jiangsu Province Centers for Disease Control and Prevention West China Hospital	Phase 1

○ 일본 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04513925	A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)	Non-small Cell Lung Cancer (NSCLC)	Drug: Atezolizumab Drug: Tiragolumab Drug: Durvalumab	Hoffmann-La Roche	Phase 3
NCT04471428	Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy	Carcinoma, Non-Small-Cell Lung	Drug: Cabozantinib Drug: Atezolizumab Drug: Docetaxel	Hoffmann-La Roche Exelixis	Phase 3